Randomized, phase III, comparative study of every-3-weeks dosing, weekly dosing of ABI-007, and weekly dosing of the conventional paclitaxel for patients with unresectable/recurrent gastric cancer refractory to prior chemotherapy containing fluoropyrimidines.

Trial Profile

Randomized, phase III, comparative study of every-3-weeks dosing, weekly dosing of ABI-007, and weekly dosing of the conventional paclitaxel for patients with unresectable/recurrent gastric cancer refractory to prior chemotherapy containing fluoropyrimidines.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms ABSOLUTE
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 06 Jun 2017 Primary endpoint (Overall Survival:OS (q1w nab-PTX (100 mg/m2) vs q1w sb-PTX (80 mg/m2))) has not been met as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Primary endpoint (Overall Survival:OS (q3w nab-PTX (260 mg/m2) vs q1w sb-PTX (80 mg/m2))) has been met as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top